References
- Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet 2013;382:1433–44.
- Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99–103.
- Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232–40.
- Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014;60:612–17.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer Journal Clin 2005;55:74–108.
- Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35–50.
- Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.
- Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
- European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012;48:599–641.
- Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with child-pugh class A cirrhosis. Am J Med 1996;101:422–34.
- Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35:75–81.
- Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008;103:1944–51.
- Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008;48:863–70.
- Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009;15:578–82.
- Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 1988;8:1679–83.
- Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000;45:1944–8.
- Hino-Arinaga T, Ide T, Kuromatsu R, Miyajima I, Ogata K, Kuwahara R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol 2012;47:569–76.
- Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50:388–93.
- Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012;55:522–9.
- Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci 2013;58:1459–76.
- Zimmermann T, Hoppe-Lotichius M, Tripkovic V, Barreiros AP, Wehler TC, Zimmermann A, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for post-transplant lymphoproliferative disease (PTLD). Eur J Intern Med 2010;21:208–15.
- Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene 2004;23:6524–34.
- Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–38.
- Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27–33.
- Bortfall och kvalitet. The National Board of Health and Welfare. Available from http://www.socialstyrelsen.se/register/dodsorsaksregistret/bortfallochkvalitet.
- Causes of Death 2012. Socialstyrelsen. 2012. Available from http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19175/2013-8-6.pdf. Cited August 2013.
- Trinchet JC. Hepatocellular carcinoma in 2014: Current situation and future prospects. Diagn Interv Imaging 2014;95:705–8.
- Levercellscancer Nationellt vårdprogram 2012. Regionala Cancercentrum i Samverkan. 2012. Available from http://www.cancercentrum.se/PageFiles/5444/NatVP_levercellscancer_20120701_fullst%C3%A4ndig.pdf. Cited 1 July 2013.
- Maddox JS, Soltani K. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008;14:1425–31.
- Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–25.
- Leung J, Dowling L, Obadan I, Davis J, Bonis PA, Kaplan MM, et al. Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci 2010;55:3218–23.
- Roman E, Smith AG. Epidemiology of lymphomas. Histopathology 2011;58:4–14.
- Beaugerie L. Lymphoma: the bete noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology 2013;145:927–30.
- Cancer incidence in Sweden 2009. Socialstyrelsen. 2010. Available from http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18204/2010-12-17.pdf. cited 10 December 2010.